Enveric announces research on non-hallucinogenic EB-003 for anxiety, depression

Enveric Biosciences announced that research highlighting the company’s lead compound, EB-003, is being presented at the 7th Neuropsychiatric Drug Summit. EB-003 is a promising neuroplastogenic and non-hallucinogenic N,N-Dimethyltryptamine DMT analog drug candidate that elicited beneficial outcomes in preclinical models of anxiety and depression. The conference is being held at the Hilton Boston Back Bay in Boston, MA on September 24-26. The presentation titled, “Non-hallucinogenic and neuroplastogenic DMT analog imparts positive behavioral outcomes in mice,” addresses the criteria researchers evaluated in the design and development of EB-003 as a non-hallucinogenic derivative of DMT for the treatment of neuropsychiatric disorders, including depression and anxiety. The poster highlights key preclinical data involving EB-003, including two mouse models demonstrating the effectiveness of EB-003 in reducing anxiety and depression, and research examining head twitch response HTR , a behavioral proxy in rodents for hallucinogenic effects in humans.